Prior work demonstrated that free water in the posterior substantia nigra (SN) was elevated in Parkinson's disease (PD) compared to healthy controls (HC) across single- and multi-site cohorts, and ...increased over 1 year in Parkinson's disease but not in relation with the iron deposition in SN with the relaxometry T2*.
The main objective of the present study was to evaluate changes in the SN using relaxometry T2*, single- and bi-tensor models of diffusion magnetic resonance imaging between PD patients and HC.
39 subjects participated in this study, including 21 HCs and 18 PD patients, in moderate stage (7 years), whose data were collected at two visits separated by approximately 2 years, underwent 3-T MRI comprising: T2*-weighted, T1-weighted and diffusion tensor imaging (DTI) scans. Relaxometry T2*, bi-tensor free water (FW), free-water-corrected fractional anisotropy, free-water-corrected mean diffusivity, single-tensor fractional anisotropy, and single-tensor mean diffusivity were computed for the anterior, posterior and whole substantia nigra.
In the anterior SN, relaxometry T2* values were greater for PD patients than HCs. In the posterior SN, free water, single- and bi-tensor mean diffusivity values were greater for PD patients than HCs. No significant change were found over time in FW/MD/R2* maps for PD patients with moderate stage.
The specific increase of R2* in the anterior SN concomitant with the specific increase of FW in posterior SN suggests a complementary aspect of the two parameters and, perhaps, different underlying pathophysiological processes.
•Relative to HCs, PD patients, for moderate stage, had increased R2* in the anterior part of SN.•Relative to HCs, PD patients, for moderate stage, had increased FW and MD in the posterior part of SN.•These results imply potentially distinct pathologies in the subparts of SN as well as distinct roles for these MRI markers.•No significant change over time in FW/MD/R2* maps for PD patients with moderate stage.
This double-blind trial was designed to determine whether rasagiline slows the progression of Parkinson's disease. As compared with delayed treatment, early treatment with rasagiline at a dose of 1 ...mg per day achieved benefits consistent with a disease-modifying effect, but 2 mg per day did not result in similar benefits.
As compared with delayed treatment, early treatment with rasagiline at a dose of 1 mg per day achieved benefits consistent with a disease-modifying effect, but 2 mg per day did not result in similar benefits.
A neuroprotective therapy that slows or stops disease progression is the major unmet medical need in Parkinson's disease.
1
Although current therapies provide beneficial effects on symptoms that help control the classic motor features of the disease (i.e., tremor, rigidity, and bradykinesia), intolerable disability eventually develops in most patients.
2
Numerous agents have neuroprotective effects in laboratory models, but none have been shown to have disease-modifying effects in patients with Parkinson's disease.
3
A limiting factor is the requirement for a clinical end point that reliably measures disease progression and is not confounded by the study intervention's effects on symptoms.
The delayed-start design . . .
Trial of Deferiprone in Parkinson’s Disease Devos, David; Labreuche, Julien; Rascol, Olivier ...
New England journal of medicine/The New England journal of medicine,
12/2022, Letnik:
387, Številka:
22
Journal Article
Recenzirano
Odprti dostop
Iron deposition in the substantia nigra has been implicated in Parkinson’s disease. Chelation with deferiprone reduced brain iron content but led to worse scores on scales of the movement disorder at ...36 weeks.
DG reports grants from the Canadian Institute of Health Research, Parkinson Canada, Brain Canada, PSI Foundation, Parkinson Research Consortium, EU Joint Programme–Neurodegenerative Disease Research, ...and University of Ottawa Brain and Mind Research Institute (UOBMRI). ÁS-F reports grants from EU Joint Programme Neurodegenerative Disease Research (JPND), and European Institute of Innovation and Technology Health, and royalties from the Massachusetts Institute of Technology.TL is on the advisory boards for An2H, receives speaker fees from UCB, and reports grants from the Michael J Fox Foundation, Health Research Board Ireland, and JPND. TM receives consultancy fees from CHDI Foundation, Sunovion, Valeo Pharma, and is part of the advisory board for AbbVie, Biogen, Roche, Medtronic, and received grants from EU Joint Programme–Neurodegenerative Disease Research, UOBMRI, Ontario Research Fund, Canadian Institute of Health Research, Michael J Fox Foundation, Parkinson Canada, Parkinson Disease Foundation/Parkinson Study Group, LesLois Foundation, Physicians Service Incorporated Foundation, and Parkinson Research Consortium.
PDF
